Screener
Avalo Therapeutics AVTX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | As of / June 30, 2026 | As of / December 31, 2025 |
|---|---|---|
| Research and development | $3,576 | $7,270 |
| License and milestones | 10,000 | — |
| Compensation and benefits | 2,805 | 4,132 |
| General and administrative | 1,160 | 682 |
| Royalty payment | — | 327 |
| Lease liability, current | 242 | 392 |
| Total accrued expenses and other current liabilities | $17,783 | $12,803 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's accrued expenses?
- Avalo Therapeutics (AVTX) reported accrued expenses of $2.81M in Q2 2026.
- How has Avalo Therapeutics's accrued expenses changed year-over-year?
- Avalo Therapeutics's accrued expenses increased by 30.9% year-over-year, from $2.14M to $2.81M.
- What is the long-term trend for Avalo Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Avalo Therapeutics's accrued expenses has grown at a 106.1% compound annual growth rate (CAGR), from $111K to $4.13M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Avalo Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude